Immunome (IMNM) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Immunome (IMNM) over the past year, gaining 41.2% versus a gain of 37.8%. Over five years, PHVS leads with a +100.5% price change compared with +9.7% for IMNM. Immunome is the larger company by market cap ($2.28 billion vs $2.18 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | PHVS |
|---|---|---|
| Share price | $19.31 | $31.12 |
| Market cap | $2.28B | $2.18B |
| 1-day change | +1.13% | -1.77% |
| YTD return | -10.10% | +14.16% |
| 1-year return | +37.83% | +41.18% |
| 5-year return | +9.65% | +100.51% |
| EPS (TTM) | $-2.52 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.06 | $43.25 |
| 52-week low | $13.49 | $20.65 |
| Distance from 52-week high | -35.76% | -28.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.29% | +83.87% |
| Average volume | 1.19M | 731.42K |
| Shares outstanding | 118.00M | 70.20M |
| Employees | 247 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
IMNM vs PHVS FAQ
Which is bigger, Immunome or Pharvaris N.V.?
Immunome (IMNM) is larger, with a market capitalization of $2.28B compared with $2.18B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, IMNM or PHVS?
PHVS returned +41.18% over the past 12 months, compared with +37.83% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.